We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Contextualizing the Evidence in Lymphomas: ADCs and Bispecific Antibodies in HL, FL, and DLBCL
John P. Leonard, MD
Matthew J. Matasar, MD
Alex Herrera, MD
Kami Maddocks, MD
Alison J. Moskowitz, MD
Sarah Rutherford, MD
NCCN Guideline Updates in DLBCL
Antibody-Drug Conjugates in FL
Application of Data from the ECHELON-1 Trial
Bispecific Antibodies in FL
Patient Selection for ADCs in First-Line DLBCL
Individualizing Frontline Treatment
First-Line Treatment of Adults with Classical Hodgkin Lymphoma
Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL
Case 1: How Should I Choose Between Single-Agent IO or IO/Chemotherapy in Patients With PD-L1 = 50% and No Driver Mutations?
Charu Aggarwal, MD, MPH
Joshua E. Reuss, MD
Case 2: In a Patient With PD-L1 1–49%, Should I Use Single Agent IO or Combination IO?
Case 4: In Patients Ineligible for Platinum-Based Chemotherapy, What Is the Ideal IO-Based Approach?
Case 5: Is There a Role for IO-Based Therapy in KRAS-Mutated NSCLC? What About Patients With Co-mutations in STK11 or KEAP1?
NSCLC Case by Case: Optimizing 1L Immunotherapy for Advanced & Metastatic Disease
Case 3: In a PD-L1 Negative Patient, Is There Any Benefit to Using Single Agent IO/Chemotherapy or Dual Agent IO/ Chemotherapy?
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education